In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Dimitrios Nasioudis to discuss minimally invasive surgery in stage IA cervical cancer and his article, "Minimally invasive hysterectomy for stage IA cervical carcinoma: a survival analysis of the National Cancer Database," which is the Lead Article in the August 2021 issue of IJGC. Dr. Nasioudis is a resident at the Hospital of the University of Pennsylvania, Philadelphia. His current interests include population science and outcomes research with an emphasis on rare gynecologic tumors. Dimitrios Nasioudis (@Dnasioudis / @PennMedicine)

IJGC Podcast

Minimally Invasive Surgery in Stage IA Cervical Cancer with Dimitrios Nasioudis

In this episode of the IJGC Podcast, Editorial Fellow Sara Nasser discusses the contents of the August issue of IJGC in Arabic.

Reviewing the August Issue with Sara Nasser (Arabic version)

In this episode of the IJGC Podcast, Editorial Fellows Emma Allanson and Erick Estrada discuss the contents of the August issue of IJGC in English.

Reviewing the August Issue with Emma Allanson and Erick Estrada (English version)

In this episode of the IJGC Podcast, Editorial Fellows Cecilia Darin and Natalia Rodriguez discuss the contents of the August issue of IJGC in Spanish.

Reviewing the August Issue with Cecilia Darin and Natalia Rodriguez (Spanish version)

In this episode of the IJGC Podcast, Editorial Fellow Enrique Chacon discusses the contents of the June issue of IJGC in Spanish.

Reviewing the July Issue with Enrique Chacon (Spanish version)

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez, is joined by Dr. Shannon Westin to discuss Phase II Trial of IUD in conservative management of endometrial cancer. Dr. Westin focuses on developmental therapeutics and the use of biomarkers to predict response and recurrence in gynecologic malignancies. She currently serves as the Director of Early Drug Development and Phase I trials in her department and is a Co-Director of the Ovarian Cancer Moonshot. She is currently the PI or co-PI for greater than 30 novel treatment trials in gynecologic malignancies. Shannon Westin (@ShannonWestin / @mdandersonnews) Highlights: 1. A fertility-sparing, non-surgical approach is increasingly necessary for individuals diagnosed with early endometrial neoplasia due to increasing prevalence of significant comorbidities and proportion of premenopausal women diagnosed with this disease. 2. Out of 57 treated patients, 47 were evaluable and 12-month response rate was 83% overall (90.6% for complex atypical hyperplasia and 66.7% for grade 1 endometrioid endometrial cancer). 3. Adverse events associated with the IUD were mild, and quality of life was not negatively impacted. 4. This study used a rigorous 12-month endpoint to demonstrate durable response rates in women with early endometrial neoplasia and identified potential biomarkers for therapy resistance.

Phase II Trial of IUD in Conservative Management of Endometrial Cancer with Shannon Westin

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Dimitrios Nasioudis to discuss the impact of SLN biopsy versus lymphadenectomy in endometrial cancer. Dr. Nasioudis is a resident at the Hospital of the University of Pennsylvania, Philadelphia. His current interests include population science and outcomes research with an emphasis on rare gynecologic tumors. Dimitrios Nasioudis (@Dnasioudis / @PennMedicine) Highlights: - Sentinel lymph node biopsy has been established as a minimalistic approach to endometrial cancer staging, with excellent diagnostic accuracy. - Data on the long-term oncologic and patient reported outcomes are greatly warranted. - For patients with stage IIIC endometrial cancer, based on a large dataset, overall survival was comparable between the sentinel lymph node biopsy alone and systematic lymphadenectomy groups.

Impact of SLN biopsy vs Lymphadenectomy in Endometrial Cancer with Dimitrios Nasioudis

In this episode of the IJGC Podcast, Editorial Fellows Anna Collins and Nicolò Bizzarri discuss the contents of the July issue of IJGC in English.

Reviewing the July issue with Anna Collins and Nicolò Bizzarri (English version)

In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Roni Nitecki to discuss pregnancy outcomes after ovarian cancer. Dr. Nitecki is a gynecologic oncology fellow at the MD Anderson Cancer Center. She received her MD from Dartmouth medical school in 2015 and completed her residency in obstetrics and gynecology at Brigham and Women's Hospital and Massachusetts General Hospital in 2019. Highlights - Fertility considerations in young women with ovarian cancer are becoming increasingly relevant. - Fear of pregnancy and adverse obstetric outcomes may be one reason that women do not pursue pregnancy after fertility sparing surgery. - Counseling about pregnancy outcomes is an important part of shared decision-making about fertility sparing surgery for ovarian cancer. - In this study, patients who conceived at least 3 months after fertility sparing surgery for ovarian cancer did not have an increased risk of adverse obstetric outcomes.

Pregnancy Outcomes after Ovarian Cancer with Roni Nitecki

Andrew Clamp (@TheChristieNHS and @OfficialUoM) In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Andrew Clamp to discuss rucaparib maintenance in recurrent ovarian cancer (ARIEL3). Dr. Clamp is an author of “Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3,” the Lead Article for IJGC’s July 2021 issue. Dr. Clamp is a Consultant and Honorary Senior Lecturer in Medical Oncology subspecializing in the treatment of gynaecological cancers. He is Chief Investigator for the MRC ICON8 Trials Programme and leads the gynaecological cancers clinical research team at The Christie. Highlights - Rucaparib provides a clinically significant prolongation of progression-free survival when used as maintenance treatment for platinum-sensitive recurrent ovarian cancer. - In the ARIEL3 trial, rucaparib extended progression-free survival versus placebo regardless of the length of the penultimate platinum-free interval, number of prior chemotherapy regimens or previous use of bevacizumab. - After extended follow-up, rucaparib was well-tolerated and its safety profile was not impacted by prior treatment history. - Maintenance PARP inhibitors should be considered for all PARP inhibitor naïve patients with recurrent high grade ovarian cancer after response to platinum-based chemotherapy.

Rucaparib Maintenance in Recurrent Ovarian Cancer (ARIEL3) with Andrew Clamp

In this episode of the IJGC Podcast, Editorial Fellows Anna Collins, Irina Tsibulak, Nicolò Bizzarri, Alex Mutombo, Enrique Chacon, and Arthur Hsu interview Professor Denis Querleu for an extended discussion of his experiences in gynecologic oncology, the importance of mentorship, and pathways for development in the field.

The Mentor's Podcast with Denis Querleu

In this episode of the IJGC Podcast, Editorial Fellow Alex Mutombo discusses the contents of the June issue of IJGC in French.

Reviewing the June Issue with Alex Mutombo (French version)

In this episode of the IJGC Podcast, Editorial Fellow Irina Tsibulak discusses the contents of the June issue of IJGC in Russian.

Reviewing the June Issue with Irina Tsibulak (Russion version)

Linda Mileshkin (@Mileshkin / @anzgog) In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Linda Mileshkin to discuss the OUTBACK Trial. Dr. Mileshkin is the Deputy Director of Medical Oncology at the Peter MacCallum Cancer Centre and a board member of the Australia and New Zealand Gynaecological Oncology Group (ANZGOG). She is a clinician researcher with a particular interest in gynaecological cancer and cancer of unknown primary (CUP). Highlights - Adjuvant chemotherapy with carboplatin and paclitaxel chemotherapy given after standard chemoradiation to women with locally advanced cervical cancer did not improve survival or relapse rates and should not be given. - There is a major unmet need to improve outcomes and access to treatment for women with cervical cancer, as this is a major cause of death and suffering worldwide, most notably in LMICs. - International cooperation is needed to complete international clinical trials in cervical cancer so that we can robustly answer important questions about how to treat this disease.

OUTBACK Trial with Linda Mileshkin

Reviewing the June Issue with Enrique Chacon(Spanish version)

The International Journal of Gynecological Cancer publishes content on novel and relevant topics in the field of gynecologic cancer. IJGC Podcast features short interview segments with leading experts discussing the latest research in their respective areas. The podcasts will serve as an interactive and education experience for all our listeners. * The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement, patient care or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others.

hubhopper

IJGC Podcast

hubhopper